On Tuesday, May 29, U.S. District Judge Sue L. Robinson ruled that “Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Inc. infringed two Pronova Biopharma Norge AS patents when they filed applications to sell a generic version of triglyceride-lowering drug Lovaza® in 2009.” The decision detailed that Teva and Par had infringed two of Pronova’s patents “ruling that the defendants had failed to prove the patents were invalid and unenforceable.” Morten Jurs, CEO of Pronova, said the company was pleased with the decision. Finnegan represented Pronova in this matter.
